IR Meeting for 2025 Q4 Results and R&D Progress
-
IR for 2025 Q4 results and R&D progress on Feb 9, 2026 at 14:00 via Zoom conference call -
Participants: institutional investors, analysts, journalists, individual investors -
IR materials to be posted on company website
KOSPI Filing Information
- Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
- Company: BUKWANG PHARMACEUTICAL IND (003000)
- Submission: BUKWANG PHARMACEUTICAL IND CO.,LTD
- Receipt: 02-02-2026
- Under KRX KOSPI Market Division